Servicio de Información Comunitario sobre Investigación y Desarrollo - CORDIS

Periodic Report Summary 1 - 3DNET (Drug Discovery and Development for Novel Eye Therapeutics)

There is an unmet clinical need for more effective treatments to halt or reverse eye diseases that lead to blindness (like age-related macular degeneration, diabetic retinopathy, and corneal inflammation) with increasing prevalence as the EU population ages. Many EU pharmaceutical and biotechnology companies, with established processes for the synthesis and physiochemical characterisation of drugs, have bespoke chemical libraries and lead drugs with potential to treat ocular disease, but lack the expertise and infrastructure to test these drugs in relevant pre-clinical models. In parallel, academic labs with excellent infrastructure to study ocular disease, lack the industry expertise to appropriately develop drugs to enter clinical trials. Thus, clinical development of ocular therapeutics is impeded in the EU due to poor collaboration among academic and industry scientists.

3D-NET establishes a European network of industry and academic partners, who exchange knowledge, people, and expertise to enhance the discovery and development of drugs that target these ocular pathologies.3DNET project is governed by IAPP Marie S. Curie-FP7 Programme, in which the final and overall aim is the international transfer of Knowledge and Technology, achieved through exchange of staff between Industry and Academic sectors. This 4 year project was initiated in September 2013.

In 3DNET, a number of compounds which may have antiangiogenic (WP1), anti-inflammatory/anti-vascular permeability (WP2) and/or cell-protectant (WP3) activity in the eye, are selected. Resources and expertise of Biologists and Chemists available at each partner are used synergistically in the consortium to develop novel ocular drugs. Our specific objectives are:

1) Discovery and development of drugs that target ocular pathologies, namely: retinal vascular permeability, unwanted blood vessel growth, inflammation and cell degeneration. Novel ophthalmic drugs will be discovered from unbiased screens of small molecules (random and customised libraries).

2)The 3D-NET consortium encompasses the capabilities and infrastructure required to test these drugs in relevant pre-clinical models of ocular disease.

To date, circa 2500 new compounds have been tested for their efficacy as potential ophthalmic drugs on different models (in vivo and in vitro), a number of drug-hits are being further validated, and 2 novel drug leads are undergoing pre-clinical development. Additionally one scientific article was published in PLOS ONE last year (PMID: 25144531) and there is currently another manuscript under preparation. Finally, 2 International Workshops have been organised in this first period.

Coinciding with our first year general meeting we organized a workshop on “Drug Discovery and Ocular Therapy” (Valladolid, 23/09/2014), at which members of the consortium, external researchers, students and patients got together to learn from each other (

The "New Frontiers in Ocular Therapeutics" workshop (Dublin 12-13 Oct 2015) brought together clinicians, patients groups, academic scientists (chemists and biologists) and Pharma together to enhance co-operation in this field. Potential new collaborations and joint applications for upcoming H2020 calls were discussed during the meeting (

The Mid Term Review Meeting of our project was celebrated on Friday 5th of June, 2015 in Dublin, hosted by the coordinator Dr Breandan Kennedy in UCD (Conway Institute). The Meeting turned out to be a really enjoyable experience with excellent presentations by fellows and partners, interesting posters and truly constructive discussions. Our project officer has confirmed that 3D-NET has successfully passed the Mid Term Review, and will therefore remain funded for the next 2 years, until at least August 2017 (

Expected overall outputs of 3DNET project are: a) enhancing intersectoral training, career development and trans-national mobility of EU researchers, b) high impact publications/priority patent applications and c) overcoming barriers that impede industry-academia partnership in the EU inhibiting the discovery/development of new-cheaper and more effective drugs for ocular disease. By enhancing the career development of European researchers, creating long-term successful collaboration between industry academia and discovering novel drugs which may improve public health, the 3D-NET consortium will contribute to European excellence and competitiveness.

Reported by

Síganos en: RSS Facebook Twitter YouTube Gestionado por la Oficina de Publicaciones de la UE Arriba